Intellia Shakes Up Expectations: A Deep Dive into Their Q1 Surprise

The CRISPR Crusade: Intellia's Ambitious Leap into the Heart of AML

A Sudden Chill for Intellia: FDA Hits Pause on Groundbreaking Gene Therapy Trial

Intellia's Big Chill: Manufacturing Woes Trigger a Wave of Downgrades

The Biotech Beat: Unpacking a Week of Breakthroughs, Billions, and Big Bets

The Daily Market Rhapsody: Unpacking Today's Big Swings and Startling Surprises

The CRISPR Conundrum: A Pioneering Gene Therapy Paused by Unexpected Risk

A CRISPR Conundrum: Intellia's Trial Halt Jolts the Biotech World

The CRISPR Horizon: Intellia's Bold Leap Into Our Genetic Future, One Edit at a Time

Biotech's Pulse: Gene-Editing's Leap, Cancer's New Fights, and What's Stirring the Industry

The Shaking Ground: Intellia's Gene-Editing Dream Hits a Harsh Reality Check with Trial Setback

Cathie Wood's ARK Invest Stacks Up on Alibaba, Baidu, and Biotech Gems in Active Week